# Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication

Study · id `cardio:ct-nct06049654` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06049654](<https://clinicaltrials.gov/study/NCT06049654>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06049654

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 104 participants.

## Technical summary

Registry record NCT06049654. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2027-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT06049654, source copy `cardio:ctgov-nct06049654-2026-09-24`, retrieved 2026-10-26)
- Started: 2024-02-01 (actual) (ClinicalTrials.gov record NCT06049654, source copy `cardio:ctgov-nct06049654-2026-09-24`, retrieved 2026-10-26)
- Primary completion: 2027-11-01 (anticipated) (ClinicalTrials.gov record NCT06049654, source copy `cardio:ctgov-nct06049654-2026-09-24`, retrieved 2026-10-26)
- Completion: 2027-11-01 (anticipated) (ClinicalTrials.gov record NCT06049654, source copy `cardio:ctgov-nct06049654-2026-09-24`, retrieved 2026-10-26)
- Countries: Italy; Spain; United Kingdom (ClinicalTrials.gov record NCT06049654, source copy `cardio:ctgov-nct06049654-2026-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06049654-2026-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication
- Condition: Aortic Valve Stenosis
- Condition: Structural Valve Deterioration
- Intervention (Device): NVT ALLEGRA TAVI System TF
- Intervention (Device): EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM
- Lead sponsor: Fundación EPIC
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Fundación EPIC (`cardio:org-fundacion-epic`)

## Provenance

Content hash: e90aa390ba7c77a418715255ca6de4831d5944af8dd8856212453bb32efd7835
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
